{"groups":[{"description":"Final Analysis with DCO on 27Nov2024","id":"FG000","title":"Dato-DXd_NSCLC"},{"description":"Final Analysis with DCO on 06May2024","id":"FG001","title":"Dato-DXd_TNBC"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"43"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"7"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"79"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"29"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"50"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Overall 168 participants were screened at 23 centers in China. A total of 119 participants were treated with Dato-DXd. For TNBC cohort, 106 participant was screened at 14 centers in China. 79 participants received Dato-DXd at the 14 centers. For NSCLC cohort, 62 participant was screened at 12 centers in China. 40 participants received Dato-DXd at 11 centers. Note: 3 centers screened both TNBC participants and NSCLC participants.","recruitmentDetails":"This Phase 1/2, open-label, multiple-cohort, single-arm study was conducted in participants with Advanced Non-Small-Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer(TNBC) in China. For TNBC cohort, first participant was screened on 11Jul2022, last participant was screened on 27Apr2023. For NSCLC cohort, first participant was screened on 29Aug2022, last participant was screened on 21Mar2023."}